Review anchor
Nuclear factor erythroid 2-related factor 2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Nuclear factor erythroid 2-related factor 2
CHEMBL1075094
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Nuclear factor erythroid 2-related factor 2 as ChEMBL target CHEMBL1075094, mapped to UniProt Q16236. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL1075094
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q16236
Nuclear factor erythroid 2-related factor 2
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Nuclear factor erythroid 2-related factor 2 matters
Nuclear factor erythroid 2-related factor 2 is reviewed as Nuclear factor erythroid 2-related factor 2 (UniProt Q16236); Nuclear factor erythroid 2-related factor 2 shows approved-linked disease relevance led by Friedreich ataxia. 3 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 1 approved drug, 86601 compounds, and 560 assays, with lead potency reaching pChEMBL 8.0.
Protein context
Nuclear factor erythroid 2-related factor 2
Nuclear factor erythroid 2-related factor 2 Sequence length is 605 aa.
Review this target as Nuclear factor erythroid 2-related factor 2, mapped to UniProt Q16236. Sequence length is 605 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q16236
Protein
Disease context
Friedreich ataxia
Nuclear factor erythroid 2-related factor 2 shows approved-linked disease relevance led by Friedreich ataxia. 3 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 3 additional disease programs remain visible in the same card. Linked drugs include OMAVELOXOLONE.
Start review with Friedreich ataxia because it currently carries approved-linked support. Linked drugs include OMAVELOXOLONE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
1 linked drug
Activity base
Portfolio and assay base
ChEMBL currently tracks 1 approved drug, 86601 compounds, and 560 assays for this target. The dominant activity type is EC50. CHEMBL4643134 is the current potency anchor at pChEMBL 8.0.
Use CHEMBL4643134 as the tractability anchor when discussing potency (pChEMBL 8.0).
Activity source · ChEMBL 36 via Core Engine
1 approved
pChEMBL 8.0
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Nuclear factor erythroid 2-related factor 2 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q16236, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why Friedreich ataxia is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
86601
Total Compounds
560
Total Assays
1
Approved Drugs
IC50: 7.0, EC50: 677.0, KD: 1.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL4643134
|
8.0 | EC50 | — |
|
|
No preferred name
CHEMBL4776211
|
8.0 | EC50 | — |
|
|
No preferred name
CHEMBL4450921
|
8.0 | EC50 | — |
|
|
No preferred name
CHEMBL5437928
|
7.7 | EC50 | — |
|
|
No preferred name
CHEMBL1197091
|
7.7 | IC50 | Clinical |
Source Header